Drugs / MHB018A
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07620405 | Jul 2027 → Jan 2030 expected | endocrine exophthalmos | Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07622108 | Dec 2026 → Jul 2028 expected | disease of orbital part of eye adnexa | Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07622121 | Dec 2026 → Jul 2028 expected | disease of orbital part of eye adnexa | Minghui Pharmaceutical (Hangzhou) Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07257185 | Mar 2026 → Aug 2027 expected | endocrine exophthalmos | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT07262476 | Jan 2026 → Jan 2029 expected | endocrine exophthalmos | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
| Phase 3 | NCT06989918 | Jul 2025 → Jul 2026 overdue | disease of orbital part of eye adnexa | Minghui Pharmaceutical (Hangzhou) Ltd | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MHB018A | “MHB018A 450mg for subcutaneous injection once every 4 weeks (Q4W)” NCT07620405 ↗ |
| Action | Inhibit | “inhibits the activity of a cell surface receptor called insulin-like growth factor-1 receptor (IGF-1R)” NCT07622108 ↗ |
| Modality | Monoclonal antibody | “MHB018A, is a monoclonal antibody” NCT07622108 ↗ |
| Route | Subcutaneous | “MHB018A 450mg for subcutaneous injection” NCT06989918 ↗ |
| Target | IGF1R | “a humanized anti-IGF1R antibody” NCT06989918 ↗ |